Cargando…
Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc)
Inflammation is a strong driver of atherosclerotic cardiovascular disease (ASCVD). There is a large unmet need for therapies that prevent or reduce excessive inflammation while avoiding systemic immunosuppression. We showed previously that selective inhibition of pro-inflammatory interleukin-6 (IL-6...
Autores principales: | Schulte, Dominik M., Waetzig, Georg H., Schuett, Harald, Marx, Marlies, Schulte, Berenice, Garbers, Christoph, Lokau, Juliane, Vlacil, Ann-Kathrin, Schulz, Juliane, Seoudy, Anna K., Schieffer, Bernhard, Rosenstiel, Philip, Seeger, Marcus, Laudes, Matthias, Rose-John, Stefan, Lützen, Ulf, Grote, Karsten, Schreiber, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218605/ https://www.ncbi.nlm.nih.gov/pubmed/35754497 http://dx.doi.org/10.3389/fphar.2022.758233 |
Ejemplares similares
-
A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling
por: Lokau, Juliane, et al.
Publicado: (2021) -
Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
por: Nikolaus, Susanna, et al.
Publicado: (2018) -
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells
por: Lokau, Juliane, et al.
Publicado: (2020) -
Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling
por: Flynn, Charlotte M., et al.
Publicado: (2019) -
Anti-Inflammatory Effects of C1q/Tumor Necrosis Factor-Related Protein 3 (CTRP3) in Endothelial Cells
por: Schmid, Andreas, et al.
Publicado: (2021)